Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 76.1%

Neg 0% Neu 76.1% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $400 price target.

Comments

No comments yet. Be the first!